Health news
The Food and Drug Administration (FDA) has granted Fast Track designation to CRV431 for the treatment of nonalcoholic steatohepatitis (NASH). CRV431 works by specifically binding to cyclophilin isomerase enzymes and inhibiting cyclophilin function with high…
AbbVie has submitted a regulatory application to the Food and Drug Administration for risankizumab-rzaa for the treatment of patients 16 years of age and older with moderate to severe Crohn disease. The application is supported…
Pharmacotherapies used in the treatment of nonalcoholic steatohepatitis (NASH) were compared in a recent systematic review and network meta-analysis published in Alimentary Pharmacology & Therapeutics. Although NASH is a common cause of chronic liver disease,…
The Food and Drug Administration has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older. Livmarli is a reversible inhibitor of the…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021